Acute myositis in a patient with systemic sclerosis after the administration of darbepoetin alpha
- PMID: 17674001
- DOI: 10.1007/s00296-007-0430-6
Acute myositis in a patient with systemic sclerosis after the administration of darbepoetin alpha
Abstract
We first describe the onset of acute myositis in a patient suffering from systemic sclerosis after the administration of darbepoetin alpha for renal failure-related anemia. Therapeutic implications and risks are discussed.
Similar articles
-
Comparison of pain and efficacy of darbepoetin alfa and epoetin Beta pegol treatment in patients receiving peritoneal dialysis.J Nippon Med Sch. 2015;82(1):21-6. doi: 10.1272/jnms.82.21. J Nippon Med Sch. 2015. PMID: 25797871 Clinical Trial.
-
A comparison of haemoglobin levels and doses in haemodialysis patients treated with subcutaneous or intravenous darbepoetin alfa: a German prospective, randomized, multicentre study.Nephrol Dial Transplant. 2008 Dec;23(12):4002-8. doi: 10.1093/ndt/gfn416. Epub 2008 Jul 30. Nephrol Dial Transplant. 2008. PMID: 18676350 Clinical Trial.
-
Subcutaneous injection pain with C.E.R.A., a continuous erythropoietin receptor activator, compared with darbepoetin alfa.Curr Med Res Opin. 2007 Dec;23(12):3025-32. doi: 10.1185/030079907X242700. Curr Med Res Opin. 2007. PMID: 17961301 Clinical Trial.
-
Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia.JAMA. 2008 Feb 27;299(8):914-24. doi: 10.1001/jama.299.8.914. JAMA. 2008. PMID: 18314434 Review.
-
Optimizing the dose and schedule of darbepoetin alfa in patients with chemotherapy-induced anemia.Oncology (Williston Park). 2006 Jul;20(8 Suppl 6):29-32. Oncology (Williston Park). 2006. PMID: 16925109 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical